Tags

Type your tag names separated by a space and hit enter

Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin.
Diagn Pathol 2011; 6:98DP

Abstract

BACKGROUND

Ampullary cancer (AC) was classified as pancreatobiliary, intestinal, or other subtype based on the expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20). We aimed to explore the association of AC subtype with patient prognosis.

METHODS

The relationship of AC subtype and expression of Osteopontin (OPN) with the prognosis of 120 AC patients after pancreaticoduodenectomy was investigated.

RESULTS

The patients had pancreatobiliary (CK7+/CK20-, n = 24, 20%), intestinal (CK7-/CK20+, n = 29, 24.2%) or other (CK7+/CK20+ or CK7-/CK20-, n = 67, 55.8%) subtypes of AC, and their median survival times were 23 ± 4.2, 38 ± 2.8 and 64 ± 16.8 months, respectively. The survival times of 64 OPN- patients (53.3%) and 56 OPN+ patients (46.7%) were 69 ± 18.4 and 36 ± 1.3 months, respectively. There was no significant effect of AC subtype on survival of OPN- patients. For OPN+ patients, those with pancreatobiliary AC had a shorter survival time (22 ± 6.6 months) than those with intestinal AC (37 ± 1.4 months, p = 0.041), and other AC subtype (36 ± 0.9 months, p = 0.010); intestinal and other AC subtypes had similar survival times.

CONCLUSIONS

The prognosis of AC patients can be estimated based on immunohistochemical classification and OPN status.

Authors+Show Affiliations

Hospital & Institute of Hepatobiliary Surgery, Chinese PLA General Hospital, 28 Fuxing Road, Beijing 100853, China.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21992455

Citation

Zhao, Xiang-Qian, et al. "Prognosis of Ampullary Cancer Based On Immunohistochemical Type and Expression of Osteopontin." Diagnostic Pathology, vol. 6, 2011, p. 98.
Zhao XQ, Dong JH, Zhang WZ, et al. Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin. Diagn Pathol. 2011;6:98.
Zhao, X. Q., Dong, J. H., Zhang, W. Z., & Liu, Z. (2011). Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin. Diagnostic Pathology, 6, p. 98. doi:10.1186/1746-1596-6-98.
Zhao XQ, et al. Prognosis of Ampullary Cancer Based On Immunohistochemical Type and Expression of Osteopontin. Diagn Pathol. 2011 Oct 13;6:98. PubMed PMID: 21992455.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin. AU - Zhao,Xiang-Qian, AU - Dong,Jia-Hong, AU - Zhang,Wen-Zhi, AU - Liu,Zhe, Y1 - 2011/10/13/ PY - 2011/08/30/received PY - 2011/10/13/accepted PY - 2011/10/14/entrez PY - 2011/10/14/pubmed PY - 2012/1/24/medline SP - 98 EP - 98 JF - Diagnostic pathology JO - Diagn Pathol VL - 6 N2 - BACKGROUND: Ampullary cancer (AC) was classified as pancreatobiliary, intestinal, or other subtype based on the expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20). We aimed to explore the association of AC subtype with patient prognosis. METHODS: The relationship of AC subtype and expression of Osteopontin (OPN) with the prognosis of 120 AC patients after pancreaticoduodenectomy was investigated. RESULTS: The patients had pancreatobiliary (CK7+/CK20-, n = 24, 20%), intestinal (CK7-/CK20+, n = 29, 24.2%) or other (CK7+/CK20+ or CK7-/CK20-, n = 67, 55.8%) subtypes of AC, and their median survival times were 23 ± 4.2, 38 ± 2.8 and 64 ± 16.8 months, respectively. The survival times of 64 OPN- patients (53.3%) and 56 OPN+ patients (46.7%) were 69 ± 18.4 and 36 ± 1.3 months, respectively. There was no significant effect of AC subtype on survival of OPN- patients. For OPN+ patients, those with pancreatobiliary AC had a shorter survival time (22 ± 6.6 months) than those with intestinal AC (37 ± 1.4 months, p = 0.041), and other AC subtype (36 ± 0.9 months, p = 0.010); intestinal and other AC subtypes had similar survival times. CONCLUSIONS: The prognosis of AC patients can be estimated based on immunohistochemical classification and OPN status. SN - 1746-1596 UR - https://www.unboundmedicine.com/medline/citation/21992455/Prognosis_of_ampullary_cancer_based_on_immunohistochemical_type_and_expression_of_osteopontin_ L2 - https://diagnosticpathology.biomedcentral.com/articles/10.1186/1746-1596-6-98 DB - PRIME DP - Unbound Medicine ER -